Beckman Coulter strenghtens laboratory automation business
Acquires of acoustic liquid handling company
Advertisement
Beckman Coulter Life Sciences announced its acquisition of Labcyte, a privately held, acoustic liquid handling company based in San Jose, California.
Labcyte is best known for its Echo® acoustic droplet ejection technology, which uses sound waves to transfer tiny amounts of liquid with unequalled speed and accuracy. This technology - the centerpiece of Labcyte’s Echo Liquid Handlers - enables walkaway convenience and integration capabilities. Labcyte technology enables faster and more cost-effective laboratory workflows in applications such as drug discovery and genomics.
“Labcyte’s unique product portfolio complements our existing liquid handling and laboratory automation business. It provides new opportunities to develop and enhance time-saving solutions for customer workflows,” said Jonathan Pratt, President, Beckman Coulter Life Sciences. “Labcyte and Beckman Coulter Life Sciences share a common vision of advancing science through discovery, enabling the faster discovery and development of life-changing advances in medicine. Together we will make a powerful team, and an invaluable resource for current and future customers around the world.”
“It has been an exciting journey—from developing acoustic liquid-dispensing technology in a garage to establishing a global presence, and now to be joining forces with a life sciences technology leader,” said Richard Ellson, CTO and a Founder of Labcyte. “Acoustic liquid handling is quickly becoming the backbone for high-throughput, automated workflows, and we look forward to accelerating growth and innovation as part of the Beckman Coulter Life Sciences team.”
Labcyte will transition into Beckman Coulter Life Sciences under the larger Danaher Life Sciences platform of companies, which generates approximately $6.5 billion in annual revenue.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Beckman Coulter Life Sciences Acquires Microbioreactor Manufacturer m2p-labs
Adapting the Power of Density Gradient Separations for Gene Therapy Analytics - DGE-AUC (Density Gradient Equilibrium AUC) highly simplified analytical method
Biomek NGeniuS | Automatic preparation machines | Beckman Coulter
Future-oriented expansion of the LUM management
LUM GmbH and Alpharmaca Inc. start working together - Strong demand from the pharmaceutical and semiconductor sectors leads to expansion of the Chinese sales network
Mechanism for potential Friedreich's ataxia drug uncovered - Discovery takes researchers one step closer to human clinical trials and could improve understanding of other diseases
Eurofins acquires LGC Forensics
Eurofins expands its presence in India
Eurofins expands in clinical diagnostics
Eurofins expands its specialty diagnosis branch - Acquiring Dutch NMDL-LCPL
Strategic peptide purification - Practical and theoretical aspects of method development using reversed phase chromatography